Current Report ESPI 10/2025

The Management Board of Ryvu Therapeutics S.A. (the “Company”) with its registered office in Kraków (the “Company”), hereby announces that on April 23, 2025, the Company has concluded a grant agreement (the “Agreement”) with the Medical Research Agency (in Polish: Agencja Badań Medycznych, “MRA”) for the co-financing of the Company’s project entitled: “ADCraft – next-generation small-molecule payloads for antibody-drug conjugates in oncology” (the “Project”). The Company had previously informed about the recommendation of the Project for co-financing in Current Report No. 2/2025 dated February 7, 2025.

The aim of the Project is to develop methods for discovering and testing new generation of payloads for Antibody-Drug Conjugates (ADC) along with a portfolio of R&D activities focused on new therapeutic modalities used in oncology.

– the total net value of the Project is: PLN 13,172,227.85;

– recommended amount of the funding: PLN 9,879,170.99;

– the planned duration of the Project: 18 months.

In case the grant agreement is concluded and the Project is implemented, the granted funding may limit the use of the Company’s own funds.

 

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

 

Legal basis: Article 17.1 of MAR

Representatives of the Issuer:

• Paweł Przewięźlikowski – President of the Management Board
• Krzysztof Brzózka – Vice-president of the Management Board